drugset / Trial / NCT00439413
Selegiline for Smoking Cessation - 1
Phase 2
Completed
246 enrolled
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-08
- Completion
- 2009-01
Publications
- Results Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, Williams J, Murtaugh C, Montoya I, Yu E, Elkashef A. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res. 2012 Mar;14(3):377-82. doi: 10.1093/ntr/ntr143. Epub 2011 Aug 16.
- Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Selegiline | Unknown | 6 mg | Other |